This RAND report puts the RHTP's inability to offset upcoming Medicaid cuts in grim perspective
www.rand.org/pubs/researc...
BREAKING: Vinay Prasad is leaving the FDA for the second time. First reported by the WSJ
www.statnews.com/2026/03/06/f...
Excited to see this piece with @michaelannica.bsky.social and @rachelsachs.bsky.social out
We looked at the Rural Health Transformation Program: Its funding formula had a clear small-state bias; we ask whether its scoring methodology also perhaps favored red states
academic.oup.com/healthaffair...
And if, as Klomp argues, "it was never meant to be used by Americans with health insurance," the website's references to "all Americans" and "every American" are misleading at best. 3/3
The TrumpRx website says, prominently, "Find the world's lowest prices on prescription drugs." And then: "TrumpRx is rewriting the script, bringing major savings on essential medications for all Americans." That's difficult to square with Klomp's remarks. 1/3
www.statnews.com/2026/03/19/c...
"[W]ith some drugs, Mr. Trump appears to have modestly narrowed the gap between European and U.S. prices. But the gap persists, and the reality does not match his hyperbole." www.nytimes.com/2026/03/18/w...
Now up at Health Affairs Forefront, Kristi Martin and I analyze the published explanations for the 2027 cycle of the Medicare drug price negotiation program. We focus on what's in (and what's not in) the explanations, as well as implications for future cycles. www.healthaffairs.org/content/fore...
New @jama.com commentary by @rachelsachs.bsky.social @dusetzinas.bsky.social &myself on biosimilar drug competition and price declines.
jamanetwork.com/journals/jam...
Glad to see STAT highlight the issue of delaying overseas launches, including linking to the public comments @rgfrank.bsky.social, Kristi Martin, and I submitted to CMS on the international reference pricing models. www.statnews.com/2026/03/24/t... www.brookings.edu/articles/com...
